Sonnet Biotherapeutics announced a collaboration with the Sarcoma Oncology Center to develop SON-1210, a treatment for metastatic pancreatic cancer, which will be evaluated in a Phase 1/2a study combining it with chemotherapy. Preclinical studies showed promising results with no significant toxicity and a notable increase in a key biomarker for anti-tumor efficacy.